Key Points
- Charles River Laboratories CAO Michael Gunnar Knell sold 6,645 shares for approximately $1.73 million at an average price of $260.38, reducing his direct ownership by 35.92% to 11,852 shares.
- CRL reported quarterly EPS of $3.02, beating estimates of $2.77, while revenue reached $1 billion but declined 2.7% year over year. The company maintained fiscal 2026 EPS guidance of $11.15–$11.45.
- Analyst sentiment remains positive, with a “Moderate Buy” consensus and 12 Buy, three Hold, and one Sell rating; several firms raised their price targets to $300, above the consensus target of $255.65.
Charles River Laboratories International, Inc. (NYSE:CRL - Get Free Report) EVP Victoria Creamer sold 4,179 shares of the business's stock in a transaction dated Thursday, August 6th. The shares were sold at an average price of $259.16, for a total value of $1,083,029.64. Following the completion of the sale, the executive vice president directly owned 30,051 shares of the company's stock, valued at $7,788,017.16. The trade was a 12.21% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Charles River Laboratories International Stock Up 3.3%
Shares of NYSE:CRL opened at $276.34 on Tuesday. The business's 50 day simple moving average is $216.74 and its two-hundred day simple moving average is $189.45. The firm has a market cap of $13.19 billion, a P/E ratio of -56.98, a PEG ratio of 2.77 and a beta of 1.38. The company has a debt-to-equity ratio of 0.92, a quick ratio of 1.04 and a current ratio of 1.35. Charles River Laboratories International, Inc. has a 52-week low of $144.26 and a 52-week high of $277.07.
Charles River Laboratories International (NYSE:CRL - Get Free Report) last announced its quarterly earnings data on Wednesday, August 5th. The medical research company reported $3.02 EPS for the quarter, beating analysts' consensus estimates of $2.77 by $0.25. The firm had revenue of $1 billion during the quarter, compared to analysts' expectations of $980.53 million. Charles River Laboratories International had a positive return on equity of 15.75% and a negative net margin of 5.96%.The company's revenue for the quarter was down 2.7% compared to the same quarter last year. During the same quarter last year, the firm posted $3.12 earnings per share. Charles River Laboratories International has set its FY 2026 guidance at 11.150-11.450 EPS. As a group, research analysts forecast that Charles River Laboratories International, Inc. will post 11.35 EPS for the current fiscal year.
Analyst Upgrades and Downgrades
CRL has been the subject of a number of recent research reports. Piper Sandler set a $300.00 price target on shares of Charles River Laboratories International in a research note on Monday. Weiss Ratings raised shares of Charles River Laboratories International from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Wednesday, July 1st. Royal Bank Of Canada lifted their price objective on shares of Charles River Laboratories International from $215.00 to $282.00 and gave the company an "outperform" rating in a report on Thursday. BNP Paribas Exane set a $250.00 target price on shares of Charles River Laboratories International in a report on Wednesday, July 1st. Finally, Barclays reaffirmed an "overweight" rating and issued a $300.00 price target on shares of Charles River Laboratories International in a research report on Wednesday, August 5th. Twelve equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Charles River Laboratories International presently has a consensus rating of "Moderate Buy" and an average target price of $255.65.
View Our Latest Stock Analysis on CRL
Institutional Investors Weigh In On Charles River Laboratories International
A number of hedge funds have recently made changes to their positions in the business. Los Angeles Capital Management LLC bought a new position in Charles River Laboratories International during the fourth quarter valued at about $42,000. Sfam LLC bought a new stake in Charles River Laboratories International in the fourth quarter worth about $43,000. Activest Wealth Management increased its stake in shares of Charles River Laboratories International by 10,900.0% during the 4th quarter. Activest Wealth Management now owns 220 shares of the medical research company's stock worth $44,000 after purchasing an additional 218 shares during the last quarter. Geneos Wealth Management Inc. lifted its stake in Charles River Laboratories International by 98.0% in the second quarter. Geneos Wealth Management Inc. now owns 293 shares of the medical research company's stock valued at $44,000 after purchasing an additional 145 shares during the last quarter. Finally, Elyxium Wealth LLC bought a new position in shares of Charles River Laboratories International during the 4th quarter worth $46,000. 98.91% of the stock is currently owned by institutional investors.
About Charles River Laboratories International
(
Get Free Report)
Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company's core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.
Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
